Andrianto A, Sudiana IK, Suprabawati DGA, Notobroto HB. Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types. F1000Research. 2023;12.

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49.

Article  Google Scholar 

Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869–74.

Article  PubMed  PubMed Central  Google Scholar 

Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

Article  PubMed  Google Scholar 

Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11:263–75.

Article  PubMed  PubMed Central  Google Scholar 

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am J cancer Res. 2020;10:1045.

PubMed  PubMed Central  Google Scholar 

Ferrari P, et al. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. 2022;23:1665.

Article  PubMed  PubMed Central  Google Scholar 

Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

Article  PubMed  Google Scholar 

Eshhar Z et al. Springer,. The T-body approach: potential for cancer immunotherapy. in Springer seminars in immunopathology. 1996;18:199–209.

Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next? Cancers. 2023;15:663.

Jayaraman J et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020;58.

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer J. 2021;11:69.

Article  PubMed  PubMed Central  Google Scholar 

Feucht J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019;25:82–8.

Article  PubMed  Google Scholar 

Velasco Cárdenas RM-H, et al. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023;24:2135–49.

Article  PubMed  PubMed Central  Google Scholar 

Patel U, et al. CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022;3:24–31.

Article  PubMed  Google Scholar 

Morgan RA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51.

Article  PubMed  PubMed Central  Google Scholar 

Fu W, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355.

Article  PubMed  PubMed Central  Google Scholar 

Zheng W, et al. Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer. J Translational Med. 2023;21:383.

Article  Google Scholar 

Ebbinghaus M, et al. Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. Int J Mol Sci. 2024;25:615.

Article  PubMed  PubMed Central  Google Scholar 

Stern LA, Jonsson VD, Priceman SJ. CAR T cell therapy progress and challenges for solid tumors. Cancer Treat Res. 2020;180:297–326. https://doi.org/10.1007/978-3-030-38862-1_11.

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone M. C. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

Article  PubMed  Google Scholar 

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3–9.

Article  PubMed  Google Scholar 

Kershaw MH, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–15.

Article  PubMed  PubMed Central  Google Scholar 

Park JR, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825–33.

Article  PubMed  Google Scholar 

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.

Article  PubMed  PubMed Central  Google Scholar 

D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell death disease. 2018;9:282.

Article  PubMed  PubMed Central  Google Scholar 

Guedan S, Ruella M, June CH. Emerging cellular therapies for cancer. Annu Rev Immunol. 2019;37:145–71.

Article  PubMed  Google Scholar 

Chmielewski M, Abken H. TRUCK: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145–54.

Article  PubMed  Google Scholar 

Chmielewski M, Hombach AA, Abken H. Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83–90.

Article  PubMed  Google Scholar 

Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697–706.

Article  PubMed  Google Scholar 

Kim DW, Cho J-Y. Recent advances in allogeneic CAR-T cells. Biomolecules. 2020;10:263.

Article  PubMed  PubMed Central  Google Scholar 

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120:26–37.

Article  PubMed  Google Scholar 

Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J cancer Res. 2019;9:228.

PubMed  PubMed Central  Google Scholar 

Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–25.

Article  PubMed  Google Scholar 

Hsu JL, Hung M-C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575–88.

Article  PubMed  PubMed Central  Google Scholar 

Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.

Article  PubMed  Google Scholar 

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. science. 2011;331:1559–1564.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.

Article  PubMed  Google Scholar 

Voutsadakis IA. HER2 in stemness and epithelial–mesenchymal plasticity of breast cancer. Clin Transl Oncol. 2019;21:539–55.

Article  PubMed  Google Scholar 

Yan M, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.

Article  PubMed  PubMed Central  Google Scholar 

Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. in Seminars in oncology. 2000;27:13–19.

Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park Peter J. 12 Kucherlapati Raju 13, Genome data analysis: Baylor College of Medicine Creighton Chad J. 22 23 Donehower Lawrence A. 22 23 24 25, & Institute for Systems Biology Reynolds Sheila 31 Kreisberg Richard B. 31 Bernard Brady 31 Bressler Ryan 31 Erkkila Timo 32 Lin Jake 31 Thorsson Vesteinn 31 Zhang Wei 33 Shmulevich Ilya 31. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.